<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00673361</url>
  </required_header>
  <id_info>
    <org_study_id>9361</org_study_id>
    <secondary_id>SR05-888</secondary_id>
    <nct_id>NCT00673361</nct_id>
  </id_info>
  <brief_title>Pilot Trial of &quot;Chemo-Switch&quot; Regimen to Treat Advanced Melanoma</brief_title>
  <official_title>Phase II Pilot Trial of &quot;Chemo-Switch&quot; Regimen of Biochemotherapy Followed by Daily Low-Dose Temozolomide Plus Sorafenib in Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is testing the &quot;chemo-switch&quot; strategy in melanoma, using biochemotherapy
      initially to shrink tumors and then switching to daily low-dose chemotherapy (temozolomide)
      together with sorafenib. The purpose of this study is to find out what effects (good and bad)
      biochemotherapy followed by temozolomide plus sorafenib have on melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>3 weeks, 6 weeks, 16 weeks, &amp; 24 weeks</time_frame>
    <description>Terminated study before accrual goal, no data analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Rate as Determined by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</measure>
    <time_frame>post-cycle 1 of low-dose temozolomide plus sorafenib, then every 3 months for up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>&quot;Chemo-Switch&quot; Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent decrescendo biochemotherapy regimen</intervention_name>
    <description>Temozolomide: 200mg/m^2, daily, PO, days 1-4
Vinblastine: 1.5mg/m^2, daily, IV, days 1-4
Cisplatin: 20mg/m^2, daily IV, days 1-4
IL (interleukin)-2: - 18 milli-International unit (MIU)/m^2, IVCI (intravenous continual infusion), day 1
9 MIU/m^2, IVCI, day 2
4.5 MIU/m^2, IVCI, days 3 &amp; 4
Interferon (IFN) alpha: 5 MIU/m^2, daily, SC (subcutaneously), days 1-5
5-day inpatient regimen, to be repeated every 21 days</description>
    <arm_group_label>&quot;Chemo-Switch&quot; Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose Temozolomide plus Sorafenib</intervention_name>
    <description>Temozolomide: 75mg/m^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks</description>
    <arm_group_label>&quot;Chemo-Switch&quot; Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have histologically or cytologically confirmed melanoma that is locally advanced
             or metastatic. Cutaneous, mucosal, ocular, and unknown primary melanoma are all
             eligible.

          -  Must have measurable disease, defined by RECIST as at least one lesion that can be
             accurately measured in at least one dimension (longest diameter to be recorded) as
             &gt;20mm with conventional techniques or &gt;10mm with spiral CT scan.

          -  May have received prior radiation therapy to one or more non-index lesions (prior
             radiation to an index lesion is allowable only if progression of the irradiated lesion
             is demonstrated, with progression defined as an increase of 20% or more in the largest
             diameter) and/or one prior vaccine therapy for metastatic disease. Prior adjuvant
             therapy with IFN alpha-2b, vaccine, and/or granulocyte-macrophage colony-stimulating
             factor (GM-CSF) is permitted. At least 4 weks must have elapsed since the completion
             of any prior therapy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Patients must have normal organ and marrow function as defined below:

          -  leukocytes &gt;3,000/uL (microliters)

          -  absolute neutrophil count &gt;1,500/uL

          -  platelets &gt;100,000/uL

          -  total bilirubin &lt;2.0mg/dL

          -  AST (Aspartate transaminase)(SGOT)/ALT (Alanine transaminase)(SGPT) &lt;2.5 X
             institutional upper limit of normal

          -  creatinine &lt;1.8mg/dL

          -  If &gt;50 years of age with one or more cardiac risk factors, must demonstrate normal
             exercise stress test, stress thallium test, or comparable cardiac ischemia evaluation.

          -  Must be at least 2 weeks out from major surgery and be free of any active infection
             requiring antibiotics.

          -  Women of child-bearing potential and men must agree to use adequate contraception
             prior to study entry and for the duration of study participation. Women must
             demonstrate a negative pregnancy test prior to initiation of protocol therapy.

          -  Ability to understand and the willingness to sign a written informed consent form.

        Exclusion Criteria:

          -  Prior chemotherapy, cytokine therapy (including IL-2 or IFN alpha), or antibody
             therapy for metastatic disease. Prior vaccine therapy is permitted.

          -  May not be currently receiving any other antineoplastic treatments, including
             chemotherapy, biologic response modifiers, radiation, vaccine, or investigational
             agents.

          -  History of brain metastases.

          -  Autoimmune disorders that could result in life-threatening complications in the
             setting of IFN alpha and IL-2 treatment.

          -  History of sensitivity to E. coli-derived products.

          -  Concurrent use of corticosteroids or any medical condition likely to require the use
             of systemic corticosteroids.

          -  A seizure disorder currently requiring anti-epileptic medication.

          -  Uncontrolled intercurrent illness including, but not limited to, hypertension, active
             infection requiring antibiotic therapy, symptomatic congestive heart failure, unstable
             angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that
             would limit compliance with study requirements.

          -  Evidence of bleeding diathesis.

          -  Currently on therapeutic anticoagulation. Prophylactic anticoagulation (such as
             low-dose warfarin) of venous or arterial access devices is allowed provided the PT,
             PTT (Partial Thromboplastin Time), and international normalized ratio (INR) are
             normal.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A Morse, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2008</study_first_submitted>
  <study_first_submitted_qc>May 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2008</study_first_posted>
  <results_first_submitted>March 20, 2013</results_first_submitted>
  <results_first_submitted_qc>March 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 26, 2013</results_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>&quot;Chemo-Switch&quot; Regimen</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>&quot;Chemo-Switch&quot; Regimen</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <description>Subjects age 18+</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>Terminated study before accrual goal, no data analysis</description>
        <time_frame>3 weeks, 6 weeks, 16 weeks, &amp; 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Terminated Studybefore Accrual Goal</title>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>Terminated study before accrual goal, no data analysis</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate as Determined by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</title>
        <time_frame>post-cycle 1 of low-dose temozolomide plus sorafenib, then every 3 months for up to 2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>&quot;Chemo-Switch&quot; Regimen</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael A Morse, M.D.</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-681-3480</phone>
      <email>morse004@mc.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

